No profile data available.
Emmaus Life Sciences, Inc. (EMMA) is a healthcare company in the blood disorder treatment drugs industry, based in Torrance, United States, with about 32 full-time employees.
It reported revenue of $12.45 million for fiscal year 2025, down 25.2% from fiscal year 2024, and net income of -$7.49 million. United States was its largest region in fiscal year 2025, with 73% of revenue. Its market capitalization was $4.23 million as of October 8, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 8, 2026.
, a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally.
Emmaus Life Sciences reported $12.45 million in revenue for fiscal year 2025, down 25.2% from $16.65 million in fiscal year 2024.
United States: 73% of revenue by region in fiscal year 2025, followed by International (26%).
$4.23 million as of October 8, 2026.
Listed companies of a similar size in the same industry (blood disorder treatment drugs) include Keros Therapeutics, Inc. (KROS), Coherus Oncology, Inc. (CHRS), Rallybio Corporation (RLYB), Syros Pharmaceuticals, Inc. (SYRS).